Patents by Inventor Robert Manguso

Robert Manguso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220057403
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates one or more biomarkers, such as inhibits one or more biomarkers listed in Table 1 and/or increases one or more biomarkers listed in Table 4, in combination with an immunotherapy.
    Type: Application
    Filed: January 9, 2020
    Publication date: February 24, 2022
    Inventors: William N. Haining, Adrienne Long, Robert Manguso
  • Publication number: 20220017921
    Abstract: The present disclosure provides vectors, methods and kits for for delivery and stable expression of CRISPR/Cas components capable of inducing genetic modification of cells, followed by recombinase-mediated excision of some or all of these components after the cells have been successfully genetically modified. The disclosed vectors and methods provide for reduced immunogenic effects arising from one or more CRISPR/Cas components. The disclosed vectors comprise coding sequences that encode a Cas protein, detectable markers and a guide RNA. The disclosed vectors provide for the subsequent genomic excision of the CRISPR/Cas components after successful genetic modification, as mediated by recombinase recognition of recombination sites flanking one or more of the disclosed coding sequences. The present disclosure further provides methods of generating a population of genetically modified tumor cells for screening a candidate target gene for cancer immunotherapy.
    Type: Application
    Filed: December 4, 2019
    Publication date: January 20, 2022
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: William Nicholas Haining, Juan Dubrot, Robert Manguso, Kathleen Yates, John Doench
  • Patent number: 11179480
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 23, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins
  • Publication number: 20200377879
    Abstract: The present invention relates, in part, to methods of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an agent that inhibits or promotes the copy number, the expression level, and/or the activity of one or more biomarkers listed in Table 1 or a fragment thereof. Also provided herein are methods of detecting ADAR1 or ISG15 dependency in a high proliferation cell (e.g., a cancer cell). Also provided are methods of detected increased interferon signaling pathway activity in a high proliferation cell (e.g., a cancer cell). Included herein are methods of treating cancer with inhibitors of ADAR1 or ISG15. Methods of screening for such inhibitors are also provided herein. Methods of identifying the likelihood of a cancer to be responsive to an ADAR1 inhibitor are also provided.
    Type: Application
    Filed: April 2, 2018
    Publication date: December 3, 2020
    Inventors: Matthew Meyerson, William N. Haining, Jeffrey Ishizuka, Robert Manguso, Hugh Gannon
  • Publication number: 20200300859
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1, such as regulators of TNF signaling/NF-?B activation (e.g., RIPK1, BIRC2, TBK1, TRAF3, RNF31, RBCK1, OTULIN, TRAF6, TAB2, and TNIP1), in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: September 24, 2020
    Inventors: William N. Haining, Robert Manguso
  • Publication number: 20200300857
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1 in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: September 24, 2020
    Inventors: William N. Haining, Robert Manguso, Adrienne Long
  • Publication number: 20200149042
    Abstract: The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits one or more biomarkers listed in Table 1, such as regulators of ubiquitin proteasome pathway (e.g., STIP1 homology and U-Box containing protein 1 (STUB 1), ubiquilin-1 (UBQLN1), and heat shock protein 90 kDa beta member 1 (HSP90B 1)), in combination with an immunotherapy.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 14, 2020
    Inventors: William N. Haining, Robert Manguso
  • Publication number: 20170360963
    Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 21, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: William N. Haining, Robert Manguso, Natalie Collins